Home Featured Page 2

Featured

Latest

Are You Attending PS2023? Here’s Where to Find Psychedelics Today in Denver

PT413 – Queering Psychedelics, The Dark History of Conversion Therapy, and The EMBARK Approach

COMPASS Pathways’ key patents upheld by the US Patent and Trademark Office

Algernon Pharmaceuticals to Present Phase 2 Ifenprodil Cough Data at the 2023 American Cough Conference

Cedar Clinical Research, by Numinus, the top enrolling clinical research site for MindMed’s Phase 2B study evaluating MM-120

Psychedelic Bulletin #138: Delix’s Non-Hallucinogenic Psychedelic Enters the Clinic; Arizona Earmarks...

Silo Pharma Commences Study of Novel Joint Homing Peptide SPU-21

PT412 – Psychedelics and Virtual Reality: Where Novel Experience, Technology, and...

Numinus to research COMP360 psilocybin therapy in treatment-resistant depression as part...

FILAMENT HEALTH ANNOUNCES INTERIM RESULTS FROM PHASE I CLINICAL TRIAL AT...

COMPASS Pathways to participate in upcoming Jefferies Healthcare Conference

Psychedelics Weekly – New LSD Research and The Challenges Facing a...

Terran Biosciences announces new breakthroughs in the chemistry of MDMA and...

Sunstone Therapies presents data at ASCO showing positive long-term follow-up results...

Data Demonstrating Long-Term Improvement in Depression in Cancer Patients Following Single...

123...216 Page 2 of 216

Are You Attending PS2023? Here’s Where to Find Psychedelics Today in...

PT413 – Queering Psychedelics, The Dark History of Conversion Therapy, and...

COMPASS Pathways’ key patents upheld by the US Patent and Trademark...

How to Get DMT: Obtaining the Spirit Molecule

Having Sex on DMT: What You Need to Know

William Leonard Pickard participating in celebration for Sasha Shulgin’s new book...

ABOUT US

PsyNews.com has a single-sector focus. We are a news platform dedicated to covering the psychedelic industry. This includes companies, startups, venture capital firms, investment banks, pharma, research, etc, anything associated with the new emerging industry and asset class. Many of the chemicals and compounds involved are LSD, psilocybin, DMT, ketamine, MDMA, ecstasy, ibogaine, analogs, derivatives, psychedelic mushrooms, fungi, psilocin, entheogens, empathogens, indocybin, magic truffles (psilocybin sclerotia), etc. They range from classical and standard to new and exotic. PsyNews.com will cover all psychedelic news in the psy industry, including current events, updates, and what’s happening everywhere in the sector in term of developments and investments. We will be tracking companies worth, valuation, ROI, financials, stock, revenue, IPO’s, and more. Along with medical, recreational, clinical trials, FDA, mindfulness, psy space, 5-HT2A receptor experiments, and so forth. Join us on an unforgettable journey to the center of the psychedelic industry.